Publications by authors named "Steven Hua"

Claim this Profile
O
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
William J Sandborn, Brian G Feagan, Geert D'Haens, Douglas C Wolf, Igor Jovanovic, Steven Y Hua

N Engl J Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis.
Evan S Dellon, Margaret H Collins, Marc E Rothenberg, Yehudith Assouline-Dayan, Larry Evans, Steven Y Hua

Clin Gastroenterol Hepatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.
Sandborn William, D'Haens Geert, Wolf Doug, Hanauer Stephen, Jovanovic Igor, Hua Steven

Am J Gastroenterol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study.
Danese Silvio, Feagan Brian, Hanauer Stephen, Jovanovic Igor, Ghosh Subrata, Hua Steven

Am J Gastroenterol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Brian G Feagan, William J Sandborn, Silvio Danese, Douglas C Wolf, Wenzhong J Liu, Steven Y Hua

Lancet Gastroenterol Hepatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results.
Peter H Gann, Ryan J Deaton, Nathan McMahon, Margaret H Collins, Evan S Dellon, Steven Ye Hua

J Allergy Clin Immunol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
Lee S Rosen, Robert Wesolowski, Raffaele Baffa, Kai-Hsin Liao, Steven Y Hua

Invest New Drugs· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
Gentry T King, Keith D Eaton, Brandon R Beagle, Christopher J Zopf, Gilbert Y Wong, Steven Y Hua

Invest New Drugs· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
Roy M Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y Hua

Arthritis Res Ther· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
Stanley B Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, Sebastiao C Radominski, Steven Y Hua

Arthritis Res Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
Ramesh Palaparthy, Chandrasekhar Udata, Steven Y Hua, Donghua Yin, Chun-Hua Cai

Expert Rev Clin Immunol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Geoffrey I Shapiro, Ulka N Vaishampayan, Patricia LoRusso, Jeremy Barton, Steven Hua

Invest New Drugs· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inference of equivalence for the ratio of two normal means with unspecified variances.
Siyan Xu, Steven Ye Hua, Ronald Menton, Kerry Barker, Sandeep Menon

J Biopharm Stat· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplicity adjustments in testing for bioequivalence.
Steven Y Hua, Siyan Xu, Ralph B D'Agostino

Stat Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inference of bioequivalence for log-normal distributed data with unspecified variances.
Siyan Xu, Steven Y Hua, Ronald Menton, Kerry Barker, Sandeep Menon

Stat Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Luis Fayad, Fritz Offner, Mitchell R Smith, Gregor Verhoef, Peter Johnson, Steven Y Hua

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%.
Martin Kaback, Stephen V Scoper, George Arzeno, John E James, Steven Y Hua

Ophthalmology· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial.
Jess T Whitson, John D Roarty, Lingam Vijaya, Alan L Robin, Robert D Gross, Steven Y Hua

J AAPOS· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
Richard A Lewis, Gregory J Katz, Mark J Weiss, Theresa A Landry, Jaime E Dickerson, Steven Y Hua

J Glaucoma· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis